Moventia maintains its commitment to supporting medical research in Spain under its partnership with the FERO Foundation. Over the last nine years, Moventia has supported pioneering projects in the field of oncology, especially prostate cancer research. However, a new research programme focused on colon cancer was recently unveiled that is being supported by Moventia and led by Dr. Joaquín Mateo at the Vall d’Hebron Institute of Oncology.

Backed by Moventia from August 2019 to February 2024, the project seeks to create an international clinical and molecular data platform for patients with prostate cancer in order to better understand the disease and improve future therapies.

More than 500 patients were recruited over the four years of this project in Spain, exceeding initial expectations, and more than 1,500 samples were collected from patients to create one of the richest biobanks anywhere in the world. Various research initiatives are also being developed, such as the use of artificial intelligence to tackle prostate cancer, development of a liquid biopsy trial to diagnose and predict relapses, and the study of communication between immune system and tumour cells to improve the effectiveness of immunotherapies.

This project will continue to recruit new patients around the world in order to reach the target of 5,000 patients and the collected samples will be used as the basis for future research and advancements in molecular medicine.

Moventia is proud of its ongoing support for medical research in Spain and hopes to make a significant contribution to the fight against cancer.